Leidos Holdings Inc (NYSE:LDOS), a key player in the bio-tech industry, has been facing several fluctuations recently.
DHS had cancelled a significant cybersecurity contract with the company, attributing it to changes in priorities. However, Leidos' potentials and growth prospects haven't gone unnoticed as Paradoxiom Capital L.P. acquired 64,863 shares and BNP Paribas Financial Markets gained 43,764 shares. On the other hand, some entities like Cresset Asset Management LLC and Ameriprise Financial Inc. reduced their holdings in the company. Despite these, promising signs were evident as Leidos scored a
$205 million contract and reaffirmed its 2025 earnings guidance.
Investing in AI to combat disease and bolster national security, the company continues to make strategic moves in technological innovation. The company's performance remains impressive with a
6.6% stock rise over the past week and strong Q1 2025 results. Simultaneously, the firm is under pressure with
large institutional owners expecting continual progress.
Leidos Holdings LDOS News Analytics from Mon, 23 Dec 2024 08:00:00 GMT to Sat, 17 May 2025 10:19:37 GMT -
Rating 3
- Innovation 7
- Information 9
- Rumor -1
